ArticleJournal of proteome research2010
Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry.
Article in Journal of proteome research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling.Cell reports methods · 2021Article
- MicroRNA Expression and Correlation with mRNA Levels of Colorectal Cancer-Related Genes.Journal of gastrointestinal cancer · 2020Article
- The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer "Omics".International journal of molecular sciences · 2019Review
- Application of targeted mass spectrometry in bottom-up proteomics for systems biology research.Journal of proteomics · 2018Review
- Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer.Journal of proteome research · 2018Article
- Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression,Molecular & cellular proteomics : MCP · 2017Article
- Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis.Oncotarget · 2017Article
- Quantitative proteomics of breast tumors: Tissue quality assessment to clinical biomarkers.Proteomics · 2017Article
- A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research.Frontiers in oncology · 2017Review
- Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer.Molecular & cellular proteomics : MCP · 2016Article
- Comparison of commercial nanoliquid chromatography columns for fast, targeted mass spectrometry-based proteomics.Future science OA · 2016Article
- Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays.Molecular & cellular proteomics : MCP · 2016Article
- Review
- Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.Methods (San Diego, Calif.) · 2015Article
- Emerging proteomic technologies for elucidating context-dependent cellular signaling events: A big challenge of tiny proportions.Proteomics · 2015Review
- Proteomics of ovarian cancer: functional insights and clinical applications.Cancer metastasis reviews · 2015Review
- Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.Molecular & cellular proteomics : MCP · 2014Article
- Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.Cancer discovery · 2013Article
- Review of software tools for design and analysis of large scale MRM proteomic datasets.Methods (San Diego, Calif.) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Reaction monitoring mass spectrometry has emerged as a powerful tool for targeted detection and quantification of proteins in clinical samples. Here, we report the use of gel electrophoresis for protein fractionation and liquid chromatography coupled to multiple reaction monitoring mass spectrometry (LC-MRM) screening for quantitative analysis of components from the Wnt/beta-catenin signaling pathway, which contributes to colon tumor formation and progression. In silico tools are used to design LC-MRM screens for each target protein. Following successful peptide detection, stable isotope labeled peptides are synthesized and developed as internal standards. Then, the assays are implemented in colon cancer cell lines to achieve detection in minimal amounts of cells, compatible with direct translation to clinical specimens. Selected assays are compared with qualitative results from immunoblotting (Westerns) and translated to individual frozen colon tissue sections and laser capture microdissected tumor cells. This LC-MRM platform has been translated from in vitro models to clinical specimens, forming the basis for future experiments in patient assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.